NeuClone
Sydney, Australia· Est.
Australian biosimilar developer using a proprietary CHO platform to bring affordable biologics to market.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian biosimilar developer using a proprietary CHO platform to bring affordable biologics to market.
OncologyImmunologyBone HealthInfectious Diseases
Technology Platform
NeuMAX is an integrated CHO‑cell platform combining the high‑viability NeuCHO cell line, optimized pNeu expression vectors, and low‑cost NeuGRO chemically defined medium to enable commercial‑scale production of complex biologics.
Opportunities
NeuClone can capture growth by leveraging its cost‑effective NeuMAX platform to launch affordable biosimilars of high‑margin blockbuster biologics, especially in emerging markets with strong price sensitivity.
Risk Factors
Key risks include regulatory approval hurdles, intense competition from established biosimilar manufacturers, and the challenge of scaling manufacturing while maintaining product quality.
Competitive Landscape
Major competitors such as Sandoz, Amgen, and Samsung Bioepis dominate the biosimilar space; NeuClone differentiates through its proprietary CHO platform and strategic manufacturing partnerships.